Articles

Doxazosin appears to work synergistically with acarbose to improve metabolic control in patients with impaired glucose tolerance.

Findings from a new study suggest that obesity per se is not a risk factor for acute organ failure or death. However, diabetes, which often develops in obese individuals, does increase the risk.

Benfotiamine prevents the endothelial dysfunction and oxidative stress that follow a meal rich in advanced glycation end (AGE) products in type 2 diabetics.

One in three adults with CVD was vaccinated against flu in 2005. One of the biggest barriers is that only about half of all cardiologists in the US stock flu vaccine in their clinics.

Orexigen Therapeutics announced that top-line results for the company’s lead obesity compound, Contrave™, demonstrated significant advantages in weight loss in a 24-week multicenter, placebo-controlled, Phase III trial. The trial will continue unblinded for an additional 24 weeks.

A Consensus Report launched at the annual meeting of the European Association for the Study of Diabetes, in Copenhagen, Denmark, is calling for urgent action to drastically improve the management of diabetes, particularly urging the increased acceptance of insulin. All patients with Type 2 diabetes, if they live long enough …

A new pharmacokinetic study to compare Nastech’s intranasal insulin to injectable insulin and Exubera(R) (insulin human [rDNA origin]) Inhalation Powder, is set to begin.

Short or poor quality sleep is associated with reduced control of blood-sugar levels in African Americans with diabetes, report researchers.

A prospective cohort study of more than 40,000 people in Japan has shown that drinking green tea can significantly cut deaths from cardiovascular disease (CVD) as well as all-cause mortality, particularly in women.

The FDA approved safety labeling revisions for rosiglitazone maleate plus glimepiride tablets (Avandaryl, made by GlaxoSmithKline) to warn of the increased risk for rosiglitazone-related cardiovascular (CV) events in patients with New York Heart Association (NYHA) class 1 and 2 cardiac status.